Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28323890 | 1.00 | TDP1 (0.49) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL2296898 | 1.00 | TDP1 (0.49) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL8042680 | 0.95 | TDP1 (0.51) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL13040189 | 0.95 | TDP1 (0.51) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL24311830 | 0.90 | TDP1 (0.49) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL7642786 | 0.89 | CA1 (0.46) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL2617386 | 0.89 | CA1 (0.46) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL7642781 | 0.89 | CA1 (0.46) | TDP1CA1CA2CA7KMT2A | |
| SCHEMBL8089276 | 0.88 | CTSK (0.55) | CTSKCTSS | |
| SCHEMBL2074989 | 0.88 | CTSK (0.55) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622981-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12527882-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4613289-A2 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3490562-B1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | UNIV LELAND STANFORD JUNIOR (US) | 2025-09-03 | — | — | EP | disclosed |
| US-20250177559-A1 | BRANCHED LIPID CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-06-05 | — | — | US | disclosed |
| US-12215341-B2 | Hybrid immolative cell-penetrating complexes for nucleic acid delivery | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4489786-A1 | BRANCHED LIPID CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | The Board of Trustees of the Leland Stanford Junior University (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240277870-A1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-08-22 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013007768-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF AS JAK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-01-17 | — | — | WO | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2003061653-A9 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LTD (GB) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003061653-A1 | 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES | PFIZER LIMITED (GB) | 2003-07-31 | — | — | WO | disclosed |
| EP-1311292-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| WO-2001097861-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622981-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | NPC1L1, NPC1, SCP2 | TDP1 1325/4885CA1 2283/4885CA2 2652/4885 |
| US-20240277870-A1 | IMMOLATIVE CELL-PENETRATING COMPLEXES FOR NUCLEIC ACID DELIVERY | RNASE1, IPO9, DNASE1L3 | TDP1 301/4885CA1 1256/4885CA2 2056/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | TDP1 910/4885CA1 3596/4885CA2 3337/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | TDP1 139/4885CA1 4498/4885CA2 3900/4885 |
| US-12527882-B2 | Immolative cell-penetrating complexes for nucleic acid delivery | CCRL2, HAVCR2, CCR3 | TDP1 1745/4885CA1 1854/4885CA2 1341/4885 |
| US-20250177559-A1 | BRANCHED LIPID CHARGE-ALTERING RELEASABLE TRANSPORTERS FOR NUCLEIC ACID DELIVERY | SLC27A1, SLC27A2, SLC7A1 | TDP1 1266/4885CA1 2929/4885CA2 1988/4885 |
| US-12215341-B2 | Hybrid immolative cell-penetrating complexes for nucleic acid delivery | RNASE1, DNASE1L3, IPO9 | TDP1 336/4885CA1 1112/4885CA2 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.